Viabahn VBX球囊扩张覆膜支架用于复杂血管腔内主动脉瘤修复开窗术的中期结局
本研究回顾性分析2015至2021年连续接受复杂EVAR并使用VBX或iCast支架作为开窗桥接支架的患者,比较两者primary patency和靶血管不稳定性。结果显示两组在腹腔干、肠系膜上动脉和肾动脉的2年primary patency无显著差异,VBX组近端 reinforcement 更常见。作者认为VBX是安全有效的选择,但需更长期随访。
要点
- VBX与iCast支架在腹腔干、肠系膜上动脉和肾动脉的2年primary patency无显著差异。
- VBX组近端 reinforcement 比例高于iCast组(23% vs 2.4%;P < .0001)。
- 两组Ic型和IIIc型内漏累积发生率及2年靶血管不稳定性无显著差异。
核心结论
- Viabahn VBX支架作为复杂EVAR开窗桥接支架是安全有效的选择,中期结局与iCast支架相当。
- 使用VBX支架可能需要近端 reinforcement 以确保开窗处充分密封。
- 需要更长期随访和更大样本系列评估长期结局和耐久性。
研究设计与样本
- 回顾性研究,纳入2015年至2021年连续接受复杂EVAR的患者。
- 比较VBX与iCast球囊扩张覆膜支架用于腹腔干、肠系膜上动脉、左肾动脉和右肾动脉开窗的桥接。
- 排除使用分支或扇形支架的靶血管。
- 主要终点包括primary patency和免于靶血管不稳定性。
主要发现
- 共292例患者接受复杂EVAR,VBX队列平均随访190天(四分位距36-384天),iCast队列平均随访804天(四分位距384-1507天)。
- 共置入677根靶血管支架,包括腹腔干134根(20%)、肠系膜上动脉175根(26%)、左肾动脉182根(27%)、右肾动脉186根(27%)及额外血管12根(2%)。
- VBX组近端 reinforcement 较iCast组更常见(23% vs 2.4%;P < .0001)。
- VBX与iCast在腹腔干(100% vs 96.4%;P = .32)、肠系膜上动脉(97.8% vs 100%;P = .14)和肾动脉(96.7% vs 99.4%;P = .11)的2年primary patency率无差异。
- VBX与iCast在Ic型和IIIc型内漏累积发生率(3.2% vs 5.6%;P = .69)及2年免于靶血管不稳定性方面无差异。
临床怎么用
- 作者认为Viabahn VBX支架可作为复杂EVAR开窗的桥接支架选项,中期结局与iCast相当。
- 作者指出使用VBX支架时可能需要近端 reinforcement 以确保开窗处充分密封。
局限性
- 需要更长期随访和更大样本系列评估长期结局和耐久性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The optimal bridging stent for fenestrations during complex endovascular aortic aneurysm repair (EVAR) has not been defined. At our institution, the Viabahn VBX is frequently used given its availability and mechanical and heparin-bonding characteristics. This study aimed to assess the performance of the Viabahn VBX vs the iCast balloon-expandable covered stents as bridging stents for fenestrations during complex EVAR. METHODS: A retrospective study of consecutive patients undergoing complex EVAR between 2015 and 2021 was performed. Celiac arteries (CAs), superior mesenteric arteries (SMAs), left renal arteries, and right renal arteries stented with fenestrations were grouped according to the type of bridging stent, VBX vs iCast. Target vessels (TV) stented with a branch or scallop were excluded. The primary end points included primary patency and freedom from TV instability. RESULTS: A total of 292 patients undergoing complex EVAR were treated using VBX or iCast with a mean follow-up of 190 days (interquartile range, 36-384 days) for the VBX cohort and 804 days (interquartile range, 384-1507 days) for the iCast cohort. A total of 677 TVs were stented, including 134 CAs (20%), 175 SMAs (26%), 182 left RAs (27%), 186 right RAs (27%), and 12 additional vessels (2%). Proximal reinforcement was more frequent with VBX than with iCast stent (23% vs 2.4%; P < .0001). There was no difference in primary patency rates at 2 years between VBX and iCast stent for CA (100% vs 96.4%; P = .32), SMA (97.8% vs 100%; P = .14), and the RAs (96.7% vs 99.4%; P = .11). There was no difference between VBX and iCast in the cumulative incidence of type Ic and type IIIc endoleaks (3.2% vs 5.6%; P = .69) or freedom from TV instability at 2 years. CONCLUSIONS: Viabahn VBX stents are a safe and effective option as bridging stents in fenestrations during complex EVAR with comparable midterm outcomes to iCast stents. However, proximal stent reinforcement may be required with VBX stent to ensure adequate sealing at the fenestrations. Longer follow-ups and larger series are required to assess long-term outcomes and durability.
引用
- Pavarino FL, Figueroa AV, Tanenbaum MT, et al. Midterm outcomes of the Viabahn VBX balloon-expandable covered stent for fenestrations during complex endovascular aortic aneurysm repair. J Vasc Surg. 2024. PMID: 39243873. doi:10.1016/j.jvs.2024.08.063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。